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Abstract 
Purpose: Antimicrobial resistance among microorganisms is a global concern. In 2003, a 
nationwide antibiotic restriction program (NARP) was released in Turkey. In this study 
we evaluated the effect of NARP on antibiotic consumption, antimicrobial resistance, and 
cost.  
Materials and Methods: The data obtained from all of the four university hospitals, and 
one referral tertiary-care educational state hospital in Ankara. Antimicrobial resistance 
profiles of 14,233 selected microorganisms all grown in blood cultures and antibiotic 
consumption from 2001 to 2005 were analyzed retrospectively.  
Results: A negative correlation was observed between the ceftriaxone consumption and 
the prevalence of ceftriaxone resistant E.coli and Klebsiella spp. (rho:-0.395, p:0.332 and 
rho:-0.627, p:0.037, respectively). The decreased usage of carbapenems was correlated 
with decreased carbapenems-resistant Pseudomonas spp. and Acinetobacter spp (rho:0.155, 
p:0.712 and rho:0.180, p:0.668, respectively for imipenem). Methicillin resistance rates of 
S.aureus were decreased from 44% to 41%. After two years of NARP 5,389,155.82 USD 
saving occurred. 
Conclusion: NARP is effective in lowering the costs and antibiotic resistance. 
Key words: Antibiotic consumption, antimicrobial resistance surveillance, restriction policy. 
Introduction 
It  is  obvious  that  antibiotics  had  saved  many 
lives since they were first introduced to medical prac-
tice.  However,  when  antibiotics  are  used  the  emer-
gence of drug resistant microorganisms is inevitable. 
The emergence of resistant microorganisms becomes 
faster when antibiotic use is inappropriate [1]. As well 
as emergence of resistant microorganisms, increased 
mortality and morbidity, adverse drug reactions and 
excessive strain on already limited healthcare budgets 
are the results of inappropriate antibiotic consump-
tion [2-4]. These findings provide compelling evidence 
of  the  need  for  more  rational  use  of  antimicrobial 
agents in all over the world [5-9]. In order to slow-
down the development and dissemination of resistant 
bacteria, restrictions on antibiotic prescribing are be-
coming more widespread [10].  
In  February  2003,  Turkish  Ministry  of  Health 
released  a  nationwide  regulation  for  antibiotic  re-
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striction.  According  to  nationwide  antibiotic  re-
striction  program  (NARP),  carbapenems,  glycopep-
tids,  piperacillin/tazobactam,  ticarcillin/clavulanate 
were considered as restricted antibiotics that could be 
used only with the approval of an infectious disease 
specialist (IDS). Parenteral quinolones, 3(rd) and 4(th) 
generation cephalosporins, netilmisin, amikacin could 
still be prescribed by all specialists just for the first 72 
h  of  treatment  but  further  utilization  required  IDS 
approval.  
In this multicenter study we aimed to assess the 
impact of the antibiotic restriction policy on the anti-
biotic  use,  financial  cost  and  resistance  patterns  of 
leading nosocomial pathogens.  
Materials and Methods  
Hospital  setting  and  antibiotic  policy:  NARP 
was initiated in Turkey in February 2003 by a central 
regulation of Ministry of Health and was announced 
nation-wide via official newspaper of the state [11]. 
This is a quasi-experimental study performed in four 
year  period,  which  included  two  years  before  and 
after of the initiation of NARP in 2003. The study in-
cluded the data obtained from all of the four univer-
sity  hospitals,  and  one  referral  tertiary-care  educa-
tional state hospital in Ankara. These hospitals have a 
total of 6668 beds.  
Microbiologic studies: Microbiology laboratory 
results  of  hospitals  were  evaluated  retrospectively. 
Significant nosocomial pathogens, namely Pseudomo-
nas spp., Escherichia coli, Klebsiella spp.,  Acinetobacter 
spp., Staphylococcus aureus obtained from at least one 
set of blood cultures of the inpatients were included. 
More than one set of the same isolates from the same 
patient were counted as one microorganism. All la-
boratories  were  using  automatic  blood  culture  sys-
tems  (Bac-Tec
  Becton-Dickinson,  BacT-ALERT
  Bi-
oMerieux)  and  performing  antimicrobial  resistance 
testing by Kirby Bauer disc diffusion method accord-
ing  to  the  recommendations  of  Clinical  Laboratory 
Standart Institute (CLSI) [12]. Resistance patterns of 
ciprofloxacin,  3(rd)  and  4(th)  generation  cephalo-
sporins, (ceftazidime, ceftriaxone, cefepime), pipera-
cillin-tazobactam,  carbapenems  (imipenem,  mero-
penem),  aminoglycosides  (amikacin,  gentamicin) 
against  aforementioned  pathogens  were  analysed. 
Bacterial  idenfications  were  performed  by  conven-
tional  methods  and  automatic  systems  (API  20E
 
strips BioMerieux, BBL Crystal
 Becton-Dickinson). 
 Antibiotic  expenditure  and  cost:  Aggregate 
amount  of  antibiotic  consumption  as  total  weight 
(gram)  and  number  of  boxes  were  calculated  from 
two databases, 1) Hospital pharmacy computer data-
bases, and 2) International Medication System (IMS). 
Because Turkey is an inflation country we have esca-
lated all antibiotic prices. The cost of antibiotics was 
calculated as US dollars (USD).  
Statistical  Analysis:  Rates  in  every  6  months 
periods of the study period were analyzed by com-
parison of proportions with the chi-square test. Cor-
relations between antibiotic resistance and consump-
tion  calculated  by  two-tailed  Spearman’s  coefficient 
(r) for non-parametric correlations. A P value of less 
than  0.05  was  regarded  as  significant.  Software 
package STATA 9.0 (USA) was used for the analysis. 
Results 
In total, 14,233 microorganisms were enrolled in 
the  study  from  2001  to  2005.  Of  which  5371  were 
E.coli, 1323 Klebsiella spp., 1101 Acinetobacter spp., 1637 
Pseudomonas  spp.,  4801  S.aureus.  Data  on  bacterial 
resistance are summarized in table 1.  
Changes in the consumption of given antimicro-
bials for two years before and after the initiation of 
NARP can be seen in table 2.  
A  negative  correlation  was  observed  between 
the  ceftriaxone  consumption  and  the  prevalence  of 
ceftriaxone  resistant  E.coli  and  Klebsiella  spp. 
(rho:-0.395,  p=0.332  and  rho:-0.627,  p=0.037,  respec-
tively).  
Inspite  of  increased  consumption  of  piperacil-
lin-tazobactam after the NARP, the resistance rates of 
E.coli  and  Klebsiella  spp.  against  piperacil-
lin-tazobactam  did  not  increase  significantly 
(rho:0.626,  p=0.096  and  rho:0.357,  p=0.385,  respec-
tively).  
The  decreased  use  of  carbapenems  was  corre-
lated  with  decreased  rate  of  carbapenem-resistant 
Pseudomonas  spp.  and  Acinetobacter  spp  (Spearman 
rho:0.155, p=0.712 and  Spearman  rho:0.180,  p=0.668, 
respectively). 
Ceftazidim  utilization  and  resistance  rate  of 
Pseudomonas spp. to this agent both had downward 
tendency after NARP. Also methicillin resistance rates 
of S.aureus were decreased from 44% to 41% during 
the study period. However, this relationship was not 
statically significant (p=0,866). 
The cost of antibiotic utilization before and after 
NARP for selected drugs is shown in Table 3. It was 
found  out  totally  5,389,155.82  USD  saved  in  the 
budget for two years period. 
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Table 1. Impact of NARP* on bacterial resistance rates for the selected antibiotics 
  Resistance rate (%)     
  Before NARP 
2001 and 2002 
After NARP 
2003 and 2004 
% Difference  p Value 
E.coli /ceftriaxone  22  34.8  +12.8  NS 
E.coli / PIP-TAZO **  16.8  24.3  +7.5  NS 
Klebsiella/ceftriaxone  29.3  39.3  +10  NS 
Klebsiella/ PIP-TAZO **  25.5  33.8  +8.3  NS 
Acinetobacter/imipenem  51.3  45  -6.3  NS 
Pseudomonas/ceftazidim  48.5  42.8  -5.7  NS 
Staph. Aureus/methicillin  44  41  -3.0  NS 
*nationwide antibiotic restriction program, **piperacillin-tazobactam  
NS:not significant, p>0.05. 
 
 
Table 2: Comparison of antibiotic consumption two years before and after the initiation of NARP*  
Restricted Antibiotics  Antibiotic consumption (grams)  % difference 
2001+2002  2003+2004 
Meropenem  113362  85236  -24.8 
Imipenem  50532  45935.2  -9.1 
Ceftazidim  60074  38129  -36.5 
Ceftriaxone  300955  190281  -36.8 
PIP-TAZO*  270594  417114  +54.1 
Cefepime  100588  121799  +21.1 
Vancomycin  113362  85236  -17.8 
Teicoplanin  50532  45935.2  -1.4 
Total  60074  38129  -11.3 
*nationwide antibiotic restriction program, **piperacillin-tazobactam  
 
 
Table 3. Comparison of cost of antibiotics 
Restricted Antibiotics  Cost (US $)  % difference 
2001+2002  2003+2004 
Meropenem  9,517,646.80  7,156,244.09  -24.8 
Imipenem  3,728,250.96  3,389,099.06  -9.1 
Ceftazidim  1,559,280.74  989,676.32  -36.5 
Ceftriaxone  7,946,415.82  5,024,179.52  -36.8 
PIP-TAZO*  2,310,030.91  3,561,111.98  +54.1 
Cefepime  1,918,011.98  2,322,463.33  +21.1 
Vancomycin  3,403,176.00  2,797,636.80  -17.8 
Teicoplanin  17,328,037.09  17,081,283.38  -1.4 
Total  47,710,850.30  42,321,694.48  -11.3 
*piperacillin-tazobactam 
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Discussion 
Antibiotics are among the most frequently pre-
scribed drugs. A close association exists between re-
sistance rate and the amount of antimicrobial agents 
used [1]. This indicates a serious need to control anti-
biotic consumption. Optimization of antibiotic usage 
not only prevents increase in resistance but also cuts 
down the healthcare costs.  
Several  strategies  for  regulating  antimicrobial 
prescribing have been proposed, such as health care 
provider  educational  programmes,  development  of 
prescribing  guidelines,  monitoring  resistance  pat-
terns, feedback activities, introduction of order forms, 
formulary  replacement  or  institutional  restrictions, 
and  limitation  of  contacts  between  physicians  and 
pharmaceutical  representatives  [13-16].  It  has  been 
reported that the requirement for approval from an 
IDS is the most effective control method [17, 18]. The 
studies on antibiotic restriction policies are generally 
about financial concerns and antibiotic utilization but 
the  bacterial  resistance  are  not  usually  co  analysed 
[19]. We conducted this comprehensive multi centric 
study to evaluate the effect of a nationwide restriction 
programme on both antibiotic consumption and an-
timicrobial resistance rates. 
Few  hospitals  had  a  restriction  policy  before 
2003 in Turkey. Five tertiary-care educational hospi-
tals from which we collected data for this study had 
already  applied  a  local  antibiotic  restriction  policy 
and  all  five  centres  had  founded  infection  control 
committees  many  years  before  the  initiation  of  the 
NARP. Even in these selected centres already apply-
ing local antibiotic restriction policies the utilisation of 
many of the restricted antibiotics was decreased and 
the trend of resistance rates became downwards after 
implementation  of  NARP.  The  amount  of  money 
saved  increased  further.  After  two  years  of  NARP 
5,389,155.82  USD  saving  occurred  in  the  selected 
drugs. The restriction policy has resulted in clear and 
immediate saving. The long term influence on medi-
cal budget may be stronger than the beginning.  The 
financial impact of antimicrobial restriction program 
has been shown both in developed and developing 
countries [6, 17, 20-23].  
 The resistance rates of given microorganisms for 
all  of  the  antibiotics  evaluated  were  not  increased 
significantly. For instance in spite of increased con-
sumption  of  piperacilin-tazobactam  (TZP)  after 
NARP resistance rates did not increase significantly. 
This finding for TZP is in accordance with the litera-
ture [24]. This finding has revealed that restricted an-
timicrobials has been started to be utilized more ra-
tionale after the initiation of NARP. Also carbapenem 
resistance rates of Pseudomonas spp and Acinetobacter 
spp decreased correlating with decreased consump-
tion of carbapenems after NARP (Spearman rho:0.155, 
p:0.712 and Spearman rho:0.180, p:0.668, respectively 
for imipenem). Falagas  et al. reported decreased re-
sistance  rates  of  Pseudomonas  aeruginosa  but  not  of 
Acinetobacter  baumannii  and  E.  coli  isolates  by  re-
striction policy [22]. Regal et al. have found imipenem 
resistance  of  Pseudomonas  aeruginosa  declined  fom 
20.5% to 12.3% with an 18% reduction in use [25]. A 
negative  correlation  was  observed  between  the 
ceftriaxone  consumption  and  the  prevalence  of 
ceftriaxone resistant E.coli and Klebsiella spp. (Spear-
man  rho:-0.395,  p:0.332  and  Spearman  rho:-0.627, 
p:0.037,  respectively).  This  finding  may  partially  be 
explained by a shift in antibiotic consumption toward 
unrestricted drugs such as second and third genera-
tion oral cephalosporines. High cephalosporine use is 
a well-known risk factor for emergence of ESBL pro-
ducing Enterobacteriacea [26]. It was shown that inap-
propriate  antibiotic  use  was  significantly  higher 
among unrestricted antibiotics than restricted ones in 
a  study  comparing  antibiotic  utilisation  before  and 
after NARP in a single centre from Turkey revealed 
125.3% increase in the use of 2nd and 3rd generation 
oral  cephalosporins  [27].  Furthermore  this  finding 
was confirmed by other studies from different parts of 
world [21, 22].   The shift toward unrestricted antibi-
otics changes the antimicrobial resistance patterns of 
certain  pathogens.  Since  parenteral  forms  of  ciprof-
loxacin  and  levofloxacin  were  not  restricted  for  the 
first three days of therapy by NARP, the consumption 
of these quinolones was unsurprisingly high. Besides 
that the use of oral quinolones for maintenance may 
contribute to the significant increase in prevalence of 
quinolone resistant E.coli strains [28, 29].  
There are several limitations of our study. First, 
we were not able to investigate whether restrictive use 
of antibiotics in these five tertiary-care settings was 
associated  with  a  change  in  frequency  of  deaths  or 
nursing expenses. Second, we investigated only the 
restricted antibiotics because of this we do not know 
the consumption rate of the antibiotics which can be 
prescribed by all physicians. Third, the study period 
after  NARP  may  not  be  long  enough  to  see  the 
changes in antimicrobial resistance. It should be kept 
in mind that there is a time lag between antibiotic use 
and possible changes in antibiotic resistance. Austin et 
al.  showed  that  the  time  scale  for  emergence  of  re-
sistance  under  constant  selective  pressure  is  much 
shorter than decay time after cessation or decline in 
the level of drug use [30]. Enne et al. showed that a 
huge decrease in sulphonamide prescribing in the UK 
did not have an effect on the prevalence of resistance Int. J. Med. Sci. 2011, 8 
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to  this  drug  in  E.coli within  a  useful  time  [31]. Alt-
hough this study comprises two years after the initia-
tion of restriction policy there is still a need for con-
tinuous surveillance studies to observe the full impact 
of  the  NARP.  Fourth,  we  calculated  antibiotic  con-
sumption  in  grams  instead  of  using  “daily  defined 
dose” (DDD) to evaluate the consumption because of 
some concerns. The DDD is a technical unit which is 
the assumed average maintenance dose per day for 
the drug’s main indication in adults and is assigned 
by the WHO collaborating centre [32]. Expression of 
data for antibiotic consumption in DDDs might not 
adequately  address  differences  in  dosage  and  for 
specific  classes  of  antibiotics  between  centres.  Also, 
DDDs  do  not  take  into  account  different  doses  for 
children. Hence the use of DDDs for adults to express 
children’s consumption might lead to under presen-
tation of this segment of users in total. All five hospi-
tals in this study have their own paediatric disease 
wards with 839 beds totally.    
In  conclusion,  although  our  study  has  afore-
mentioned limitations and the antibiotic restriction is 
a controversial issue from many points of view (ethi-
cal,  pharmaceutical,  patient  benefit  etc.),  this  is  the 
first multi centric study from Turkey which evaluates 
the  effect  of  NARP  on  both  antibiotic  consumption 
and antimicrobial resistance rates and indicates that 
NARP in Turkey was effective in lowering the costs 
and antibiotic resistance. 
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